Fareva Group

Fareva Group, also known as a French pharmaceutical firm, is headquartered in France and provides packaging services for a range of pharmaceutical products. The company’s portfolio includes packaging for COVID‑19 vaccines, notably for CureVac’s vaccine candidate, as well as for other medicines such as Viagra. It operates within the pharmaceutical supply chain, focusing on the final‑stage preparation of drug products for distribution. This specialization places it in a niche role where regulatory compliance and sterile handling are critical to maintaining product integrity. The firm’s activities support both pandemic‑response efforts and routine pharmaceutical markets across Europe and potentially beyond.

In December 2020, the firm experienced a cyberattack that disrupted its vaccine packaging operations, halted production and placed employees on indefinite unemployment leave. The incident occurred amid heightened concern following a separate cyber intrusion affecting the European Medicines Agency, which had compromised documents submitted by Pfizer for vaccine authorization. While the company did not publicly confirm ransomware involvement, the attack clearly impacted critical packaging activities for multiple pharmaceutical products. Management remained silent on operational specifics despite the evident production standstill, leaving many details of the breach undisclosed. The available sources do not disclose the firm’s size, ownership structure, or any parent‑subsidiary relationships, so those aspects remain undetermined from the provided information.